Vaginal administration of a combined oral contraceptive containing norethisterone acetate

Souka, Abdel Razak; Kamel, M. M.; Einen, Moustafa A.; Saleh, F.; Sallam, Hassan

doi:10.1016/0010-7824(85)90057-5

Cited by 5 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past decades, there have been questions of whether the official labelled oral estrogens can be used to treat GSM via vaginal administration. Several studies were conducted both in postmenopausal and premenopausal women showing that the benefits from vaginal administration of several oral estrogens were not inferior to standard oral administration [ 14 – 16 ]. To our knowledge, there were no published studies on the use of the country-wide available conjugated estrogens tablet in improving FSD with vaginal administration.…”

Section: Introductionmentioning

confidence: 99%

Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial

et al. 2020

View full text Add to dashboard Cite

Background: Female sexual dysfunction (FSD) is prevalent in women with genitourinary syndrome of menopause (GSM). Vaginal estrogen is effective GSM treatment. This study was primarily aimed to evaluate the effects of vaginal administration of conjugated estrogens tablet on postmenopausal FSD using the Female Sexual Function Index (FSFI). Secondary aims were to evaluate vaginal pH, Vaginal Maturation Value (VMV), Normal Flora Index (NFI) and Most Bothersome Symptoms (MBS) changes. Methods: A double-blind trial was conducted in postmenopausal women with FSD (FSFI ≤26.55). Sixty-seven participants were randomized into two arms; vaginally administered conjugated estrogens tablet (0.625 mg, daily for 3 weeks then twice weekly for 9 weeks, n = 33), or placebo (n = 34). Results: There was no significant improvement of FSFI observed in estrogens arm compared to placebo in each domain and overall index (p = 0.182). The estrogens significantly improved vaginal pH and VMV, toward more acidity (p = < 0.001), higher VMV (p = < 0.001) and more superficial cells (p = < 0.001). We observed no significant difference in NFI and MBS between arms (p = 0.282, 0.182). Conclusion: We found no significant changes in FSFI, NFI, and MBS, but significant improvement in vaginal pH and VMV in postmenopausal women with FSD treated with vaginally administered conjugated estrogens tablet. Few side-effects were reported.

show abstract

Section: Introductionmentioning

confidence: 99%